Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Firmonertinib · AST-2818

Small molecule · Inhibitor of epidermal growth factor receptor T790M mutant (EGFR) · developed by ArriVent BioPharma

Phase 3 Most advanced trial

AVBP Developer

3 Registered trials

What is Firmonertinib?

Firmonertinib is an orally available small molecule that selectively binds and inhibits the tyrosine kinase activity of the EGFR T790M resistance mutant. It is being studied in non-small cell lung cancer, including tumors with EGFR and HER2 exon 20 mutations and uncommon EGFR mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AST-2818, Furmonertinib
Drug type: Small molecule
Targets: epidermal growth factor receptor T790M mutant (EGFR)
Mechanism: Inhibitor of epidermal growth factor receptor T790M mutant (EGFR)
Pathways: EGFR signaling, tumor cell proliferation, tumor vascularization
Therapy area: Oncology
Developer: ArriVent BioPharma, Inc. (AVBP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: A49A7A5YN4

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07010419	Phase 3	NSCLC	Recruiting	AVBP
NCT05607550	Phase 3	Metastatic Non-Small Cell Lung Cancer	Active not recruiting	AVBP
NCT05364073	Phase 1	Non-Small Cell Lung Cancer (NSCLC)	Active not recruiting	AVBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adjuvant TreatmentAdvanced Non-Small Cell Lung CancerEGFR Exon 20 MutationsEGFR Uncommon Mutations, Including G719X and S768IHER2 Exon 20 MutationsMetastatic Non-Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)NSCLC

Other drugs acting on EGFR

Neratinib FDA approved Osimertinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 ALX2004 Phase 1 BH-30643 Phase 1/2 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Enozertinib Phase 1/2 Ficerafusp Alfa Phase 2/3 FPI-2053 Phase 1 Izalontamab Brengitecan Phase 2/3 Silevertinib Phase 1/2

More from ArriVent BioPharma

ARR-002 Phase 1 ARR-217 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVBP page.

Follow AVBP, the company behind Firmonertinib

See AVBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVBP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z